INMB: INmune Bio, Inc. Stock

by  •  • Comments Off on INMB: INmune Bio, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 167.62
Enterprise Value ($M) 149.19
Book Value ($M) 32.10
Book Value / Share 1.40
Price / Book 5.22
NCAV ($M) 15.20
NCAV / Share 0.66
Price / NCAV 11.03

Profitability (mra)
Return on Invested Capital (ROIC) -1.20
Return on Assets (ROA) -0.90
Return on Equity (ROE) -1.45

Liquidity (mrq)
Quick Ratio 3.14
Current Ratio 3.14

Balance Sheet (mrq) ($M)
Current Assets 22.66
Assets 39.56
Liabilities 7.46
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.01
Operating Income -42.63
Net Income -42.08
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -33.36
Cash from Investing 0.00
Cash from Financing 18.21

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-10 13G/A Praetorian PR LLC 7.20 33.76
10-25 13G Highbridge Capital Management Llc 6.60
10-02 13G/A Xencor Inc 9.60 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPO
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 32,234 152,330 21.16
2025-04-16 63,761 220,414 28.93
2025-04-15 37,855 184,483 20.52
2025-04-14 29,344 134,180 21.87

(click for more detail)

Similar Companies
INDP – Indaptus Therapeutics, Inc. INKT – MiNK Therapeutics, Inc.
INM – InMed Pharmaceuticals Inc. INO – Inovio Pharmaceuticals, Inc.
INTS – Intensity Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io